Broadfin Capital

Investor type Hedge Fund

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 14
Average round size
info
The average size of a deal this fund participated in
$73M
Portfolio companies 13
Lead investments 2
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.07
Exits 11
Key employees 1
Stages of investment
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Pharmaceutical
  • Biopharma
Summary

The company was established in North America in United States. The main department of described VC is located in the New York.

We also calculated 1 valuable employee in our database.

The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the Broadfin Capital, startups are often financed by CMEA Capital, Shmuel Kabili, New Enterprise Associates. The meaningful sponsors for the fund in investment in the same round are OrbiMed, Deerfield, Cormorant Asset Management. In the next rounds fund is usually obtained by Yelin Lapidot Investment House, Sectoral Asset Management, Rock Springs Capital.

Among the various public portfolio startups of the fund, we may underline Iovance Biotherapeutics, Advaxis, RedHill Biopharma Among the most successful fund investment fields, there are Health Care, Health Diagnostics. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has specific favorite in a number of founders of portfolio startups. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.

The fund is constantly included in less than 2 deals per year. Deals in the range of 50 - 100 millions dollars are the general things for fund. Speaking about the real fund results, this VC is 2 percentage points more often commits exit comparing to other organizations. The higher amount of exits for fund were in 2014. The important activity for fund was in 2015. Comparing to the other companies, this Broadfin Capital performs on 71 percentage points more the average number of lead investments.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Broadfin Capital:
Typical Co-investors
Broadfin Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Broadfin Capital:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
2P Telecom and Communicati on Co. -
Andover Ventures -
Beijing Rongjin Borui Touzi Zixun Youxian Gongsi Beijing, China, Tongzhou
Brookfield Renewable Partners Canada, Hamilton, Ontario
BVC Ventures India, Maharashtra, Mumbai
Byron Asset Management England, London, United Kingdom
CleanFin Capital -
Family Office -
Fullscreen California, Culver City, United States
Jetstream Capital Franklin, Tennessee, United States
Kois Invest -
Macomb County Michigan, Mount Clemens, United States
Patni Group India, Maharashtra, Mumbai
PJ Tech Catalyst Athens, Attiki, Greece
Sage Capital India, Maharashtra, Mumbai
Tau Consortium -
Tottori Capital Japan, Tottori, Tottori Prefecture
WeWork Labs New York, New York, United States
Woven Capital Japan, Tokyo

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Arch Oncology

Biotechnology
$105M27 Apr 2021 California, United States

Sonendo

Biotechnology
Health Care
Medical
$85M06 Jan 2020 California, United States

BioDelivery Sciences International

Biotechnology
Life Science
Medical
Pharmaceutical
$50M17 May 2018 Raleigh, North Carolina, United States

Strata Skin Sciences

Medical Device
$17M02 Apr 2018 Horsham Township, Pennsylvania, United States

Iovance Biotherapeutics

Biotechnology
Health Care
Medical
$100M03 Jun 2016 New York, New York, United States

Recro Pharma

Biotechnology
Clinical Trials
Health Care
Pharmaceutical
$16M13 Jul 2015 Pennsylvania, United States

Ardelyx

Biotechnology
Health Care
Medical
$77M22 Jun 2015 Fremont, California, United States

Aralez Pharmaceuticals

Alternative Medicine
Biotechnology
Health Care
Medical
$350M08 Jun 2015 New York, United States

Advaxis

Biotechnology
Health Diagnostics
Pharmaceutical
$23M19 Feb 2015 New Jersey, United States

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Broadfin Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: